Cost of septic and aseptic revision total knee arthroplasty: a systematic review.
Cost
Economic burden
Knee
Revision
Systematic review
Total knee arthroplasty
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
18 Aug 2021
18 Aug 2021
Historique:
received:
02
08
2021
accepted:
04
08
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
21
8
2021
Statut:
epublish
Résumé
The increasing incidence of primary total knee arthroplasty (TKA) has led to an increase in both the incidence and the cost burden of revision TKA procedures. This study aimed to review the literature on the cost of revision TKA for septic and aseptic causes and to identify the major cost components contributing to the cost burden. We searched MEDLINE (OvidSp), Embase, Web of Science, Cochrane Library, EconLit, and Google Scholar to identify relevant studies. Selection, data extraction and assessment of the risk of bias and cost transparency within the studies were conducted by two independent reviewers, after which the cost data were analysed narratively for 1- or 2-stage septic revision without re-revision; 2-stage septic revision with re-revision; and aseptic revision with and without re-revision, respectively. The major cost components identified in the respective studies were also reported. The direct medical cost from the healthcare provider perspective for high-income countries for 2-stage septic revision with re-revision ranged from US$66,629 to US$81,938, which can be about 2.5 times the cost of 1- or 2-stage septic revision without re-revision, (range: US$24,027 - US$38,109), which can be about double the cost of aseptic revision without re-revision (range: US$13,910 - US$29,213). The major cost components were the perioperative cost (33%), prosthesis cost (28%), and hospital ward stay cost (22%). Septic TKA revision with re-revision for periprosthetic joint infection (PJI) increases the cost burden of revision TKA by 4 times when compared to aseptic single-stage revision and by 2.5 times when compared to septic TKA revision that does not undergo re-revision. Cost reductions can be achieved by reducing the number of primary TKA that develop PJI, avoidance of re-revisions for PJI, and reduction in the length of stay after revision. PROSPERO; CRD42020171988 .
Sections du résumé
BACKGROUND
BACKGROUND
The increasing incidence of primary total knee arthroplasty (TKA) has led to an increase in both the incidence and the cost burden of revision TKA procedures. This study aimed to review the literature on the cost of revision TKA for septic and aseptic causes and to identify the major cost components contributing to the cost burden.
METHODS
METHODS
We searched MEDLINE (OvidSp), Embase, Web of Science, Cochrane Library, EconLit, and Google Scholar to identify relevant studies. Selection, data extraction and assessment of the risk of bias and cost transparency within the studies were conducted by two independent reviewers, after which the cost data were analysed narratively for 1- or 2-stage septic revision without re-revision; 2-stage septic revision with re-revision; and aseptic revision with and without re-revision, respectively. The major cost components identified in the respective studies were also reported.
RESULTS
RESULTS
The direct medical cost from the healthcare provider perspective for high-income countries for 2-stage septic revision with re-revision ranged from US$66,629 to US$81,938, which can be about 2.5 times the cost of 1- or 2-stage septic revision without re-revision, (range: US$24,027 - US$38,109), which can be about double the cost of aseptic revision without re-revision (range: US$13,910 - US$29,213). The major cost components were the perioperative cost (33%), prosthesis cost (28%), and hospital ward stay cost (22%).
CONCLUSIONS
CONCLUSIONS
Septic TKA revision with re-revision for periprosthetic joint infection (PJI) increases the cost burden of revision TKA by 4 times when compared to aseptic single-stage revision and by 2.5 times when compared to septic TKA revision that does not undergo re-revision. Cost reductions can be achieved by reducing the number of primary TKA that develop PJI, avoidance of re-revisions for PJI, and reduction in the length of stay after revision.
TRIAL REGISTRATION
BACKGROUND
PROSPERO; CRD42020171988 .
Identifiants
pubmed: 34407779
doi: 10.1186/s12891-021-04597-8
pii: 10.1186/s12891-021-04597-8
pmc: PMC8371784
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
706Informations de copyright
© 2021. The Author(s).
Références
Infect Dis (Lond). 2019 May;51(5):348-355
pubmed: 30938200
Clin Orthop Relat Res. 2006 May;446:29-33
pubmed: 16672868
J Infect Public Health. 2016 Jul-Aug;9(4):494-8
pubmed: 26829894
N Z Med J. 2016 Apr 01;129(1432):51-8
pubmed: 27356252
J Arthroplasty. 2015 Sep;30(9):1492-7
pubmed: 25865815
J Arthroplasty. 2016 Sep;31(9):1862-5
pubmed: 27105556
J Arthroplasty. 2013 Oct;28(9):1513-20
pubmed: 23845765
J Arthroplasty. 2014 May;29(5):929-32
pubmed: 24140271
J Arthroplasty. 2016 May;31(5):952-6
pubmed: 26703194
J Arthroplasty. 2014 May;29(5):903-5
pubmed: 24332969
Orthopedics. 1995 Sep;18(9):871-3
pubmed: 8570494
Biomed Res Int. 2018 Sep 25;2018:8987104
pubmed: 30356391
Bone Joint J. 2020 Sep;102-B(9):1176-1182
pubmed: 32862687
J Hosp Infect. 2018 Dec;100(4):378-385
pubmed: 29906490
Med J Aust. 2019 Feb;210(3):135-141
pubmed: 30656689
Knee Surg Relat Res. 2018 Jun 1;30(2):107-114
pubmed: 29843197
Knee. 2020 Oct;27(5):1676-1680
pubmed: 33012635
Infect Control Hosp Epidemiol. 2000 May;21(5):311-8
pubmed: 10823563
Clin Orthop Relat Res. 2010 Jan;468(1):45-51
pubmed: 19554385
Clin Orthop Relat Res. 2017 Sep;475(9):2194-2201
pubmed: 28573549
J Arthroplasty. 2010 Sep;25(6 Suppl):103-7
pubmed: 20570103
Knee Surg Sports Traumatol Arthrosc. 2010 Jul;18(7):945-8
pubmed: 20148322
PLoS One. 2017 Jan 20;12(1):e0169558
pubmed: 28107366
Pharmacoecon Open. 2021 Jun;5(2):331-337
pubmed: 33237525
J Arthroplasty. 2008 Oct;23(7):984-91
pubmed: 18534466
Acta Chir Orthop Traumatol Cech. 2019;86(3):173-180
pubmed: 31333180
ScientificWorldJournal. 2012;2012:196515
pubmed: 22619626
J Arthroplasty. 2016 Mar;31(3):583-9.e1
pubmed: 26699673
J Arthroplasty. 2018 Feb;33(2):324-330.e1
pubmed: 29066112
Clin Orthop Relat Res. 1995 Feb;(311):136-41
pubmed: 7634568
J Orthop Surg Res. 2019 Jun 27;14(1):196
pubmed: 31248432
Clin Orthop Relat Res. 1996 Oct;(331):140-5
pubmed: 8895630
Clin Orthop Surg. 2020 Dec;12(4):470-476
pubmed: 33274024
J Arthroplasty. 2016 Jul;31(7):1400-1406.e3
pubmed: 26880328
Orthopedics. 1999 Feb;22(2):195-9
pubmed: 10037333
Bone Joint J. 2016 Jan;98-B(1 Suppl A):105-12
pubmed: 26733654
Clin Orthop Relat Res. 2006 May;446:221-6
pubmed: 16672891
Knee Surg Sports Traumatol Arthrosc. 2019 May;27(5):1418-1426
pubmed: 30128685
Pharmacoeconomics. 2011 Aug;29(8):653-71
pubmed: 21604822
Orthopedics. 1996 Feb;19(2):137-9
pubmed: 8834288
J Bone Joint Surg Am. 2021 Feb 17;103(4):312-318
pubmed: 33252589
J Arthroplasty. 2015 Jun;30(6):931-8.e2
pubmed: 25727999
J Arthroplasty. 2012 Sep;27(8 Suppl):61-5.e1
pubmed: 22554729
Int J Technol Assess Health Care. 2005 Spring;21(2):240-5
pubmed: 15921065
Value Health. 2013 Mar-Apr;16(2):231-50
pubmed: 23538175
J Bone Jt Infect. 2018 Sep 8;3(4):197-202
pubmed: 30416943
Clin Orthop Relat Res. 2002 Nov;(404):7-13
pubmed: 12439231
Orthop Traumatol Surg Res. 2019 Feb;105(1):185-190
pubmed: 30413338
Eur Rev Med Pharmacol Sci. 2019 Apr;23(2 Suppl):217-223
pubmed: 30977889
Braz J Infect Dis. 2010 Jul-Aug;14(4):356-9
pubmed: 20963320
Bone Joint J. 2015 Feb;97-B(2):197-201
pubmed: 25628282
J Eval Clin Pract. 2009 Jun;15(3):451-9
pubmed: 19366392